Lipodystrophy Workshop (IWADRW) 6th Washington 2004

6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (IWADRLH) 26-28 October 2004, Washington

Nucleoside analogue-related mitochondrial toxicity and link to lipoatrophy: effect of non-thymidine analogues abacavir and tenofovir

Nucleosides reduce PPAR-gamma: a role for rosiglitazone without thymidine analogues?

Potential for uridine to treat mitochondrial toxicity: still only in vitro data

25% patients take Kaletra on an empty stomach: dietary advice often missed at ‘centre of excellence’

rHGH reduces central fat accumulation in adolescent lipodystrophy

Weight loss is associated with elevated PBMC proviral DNA levels

Coronary artery bypass graft is safe in HIV-positive patients but shows higher risk of longer term events

Endothelial dysfunction similar in ARV-experienced and -naive patients

Pravastatin improves lipid profiles but not endothelial function

Indinavir impairs endothelial function without insulin resistance

Treatment interruptions improve lipids within four weeks: IL-2 has no metabolic effect

Improvement of lipids following switch to tenofovir

HCV coinfection linked to discontinuing ART due to toxicity

Restorative treatments for HIV-associated lipoatrophy